LimmaTech Biologics

LimmaTech Biologics AG, based in Schlieren Zurich, Switzerland, is a clinical stage biopharmaceutical company specializing in the development of innovative vaccines to combat antimicrobial resistant pathogens. The company leverages its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches, to prevent increasingly untreatable microbial infections. LimmaTech's pioneering vaccine development technologies have built a robust pipeline of vaccine programs aimed at protecting against and preventing severe infections caused by pathogens resistant to antimicrobial treatments. The company serves healthcare providers and institutions globally, operating within the biopharmaceutical market. LimmaTech generates revenue through the development and commercialization of its vaccine candidates, as well as potential partnerships and licensing agreements. The business model focuses on leveraging decades of experience in vaccine technologies and pathogen understanding to tailor vaccine approaches that protect lives and reduce the threat of microbial resistance.

Keywords: antimicrobial resistance, vaccine development, biopharmaceutical, clinical stage, multivalent technology, pathogen-specific, microbial infections, healthcare providers, commercialization, licensing agreements.